Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE-AI: EXS21546 plus Nivolumab in Advanced Solid Tumours
NCT05920408Phase 2Terminated
- Sponsor
- Exscientia
- Start
- Apr 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of EXS-21546 in renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), sponsored by Exscientia. Started Apr 2023; status: terminated.
02
Drugs
EXS-21546
03
Conditions
renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05920408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920408.